Evaluating COVID-19 immunity and reinfection risk

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the protective effect of immune barriers against secondary COVID-19 infections following vaccination or infection with the Omicron variant. It will involve 300 participants, primarily medical staff, who will be monitored over 48 weeks for COVID-19 antibody levels and symptoms of reinfection. Participants will undergo regular testing for COVID-19 antibodies and nucleic acid, with follow-up visits scheduled every few weeks to track their health status and any potential reinfections.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. No age limit, no gender limit;
2. Medical staff, administrative and logistics staff who work in the Third Affiliated Hospital of Sun Yat-Sen University or other participants who can cooperate with the follow-up for 48 weeks;
3. The participants need to be sure whether they have ever been infected with COVID-19, and need to be clearly remember the time when they first infected with COVID-19.

Exclusion Criteria:

1. Have the following serious respiratory diseases: such as asthma, bronchiectasis, chronic obstructive pulmonary disease, pulmonary interstitial disease, tuberculosis and other respiratory diseases that may interfere with symptom observation;
2. Those with other serious diseases or disease history that affect immune function, including but not limited to uncontrolled and unresectable malignant tumors,hematological diseases, cachexia, active bleeding, severe malnutrition, mental diseases, autoimmune diseases, HIV, etc.
3. Those who have long-term assignment plans and cannot return to the hospital regularly for follow-up.

Where it's running

• The Third Affiliated Hospital of Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose versus standard-dose flu vaccine for lung transplant recipients

  This study will test whether two yearly doses of the high‑dose flu vaccine produce stronger immune responses than two yearly standard‑dose flu vaccines in people who have received a lung transplant.

  Recruiting Phase 2 Vanderbilt University Medical Center · Nashville, Tennessee · NCT07192458

• Monocyte HLA-DR monitoring to detect immune weakness in severe intra-abdominal infections at risk for fungal invasion

  This will test whether measuring monocyte HLA-DR can reveal innate immune weakness in adult ICU patients with severe intra‑abdominal infections who are at risk for invasive Candida.

  Recruiting Central Hospital, Nancy, France · Vandœuvre-lès-Nancy · NCT07130799

• How COVID-19 affected fitness, sleep, diet, and blood pressure

  This project will see if past COVID-19 or long COVID is linked to changes in fitness, physical activity, blood pressure, sleep, and mental stress in adults aged 18 to 75.

  Recruiting Indiana University · Bloomington, Indiana · NCT07128095

• Ibuzatrelvir alone or with remdesivir for severely immunocompromised adults with COVID-19

  This will test whether ibuzatrelvir, taken alone or together with remdesivir, helps severely immunocompromised adults who recently developed COVID-19 symptoms.

  Recruiting at 148 sites Phase 3 Pfizer · Canoga Park, California and 158 other locations · NCT07013474

• Exploring immune responses to yellow fever vaccination

  This study is testing whether yellow fever and typhoid vaccines can boost the immune system's ability to fight off other infections, and it involves collecting blood samples from participants after they get vaccinated.

  Recruiting Institut Pasteur · Paris · NCT06718127

• Next generation inhaled COVID-19 vaccine

  This study is testing a new inhaled COVID-19 vaccine to see if it is safe and can boost the immune response in people who have already had at least three doses of an mRNA COVID vaccine.

  Recruiting at 2 sites Phase 2 McMaster University · Halifax, Nova Scotia and 1 other locations · NCT06381739

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.